Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388104 | PMC |
| http://dx.doi.org/10.55730/1300-0144.5448 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study: A Randomized Clinical Trial.
JAMA Ophthalmol
April 2025
Department of Ophthalmology, Grossman School of Medicine, New York University, New York, New York.
Importance: Evidence regarding suppressive valacyclovir treatment on postherpetic neuralgia is necessary to guide care.
Objective: To test the hypothesis that suppressive treatment with 1000 mg/d of oral valacyclovir for 12 months reduces the prevalence, severity, and duration of postherpetic neuralgia compared with placebo at 12 and 18 months in participants with herpes zoster ophthalmicus (HZO).
Design, Setting, And Participants: Multicenter, placebo-controlled randomized clinical trial including 527 immunocompetent, nonpregnant adults with history of HZO rash, documented keratitis, or iritis within 1 year and an estimated glomerular filtration rate of 45 mL/min/1.
Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial.
JAMA Ophthalmol
April 2025
Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Importance: High-quality evidence regarding suppressive valacyclovir treatment in herpes zoster ophthalmicus (HZO) is necessary to guide care.
Objective: To determine whether suppressive valacyclovir compared with placebo delays the occurrence of new or worsening stromal keratitis (SK), endothelial keratitis (EK), iritis, or dendriform epithelial keratitis (DEK) during 12 months of treatment and if treatment benefit persisted at 18 months (secondary end point).
Design, Setting, And Participants: The Zoster Eye Disease Study (ZEDS) was a randomized clinical trial conducted in 95 sites from November 2017 to June 2024.
Hemophagocytic Lymphohistiocytosis in a Remote Kidney Transplant Recipient Triggered by HSV Infection With Complete Recovery: An Educational Case Report.
Can J Kidney Health Dis
May 2024
Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Rationale: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease characterized by excessive immune activation. It is more commonly seen in children but increasingly recognized in adults. Primary HLH relies on a genetic predisposition, whereas secondary HLH develops in the context of infections, malignancies, or autoimmune diseases.
View Article and Find Full Text PDFLow-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk.
Turk J Med Sci
August 2022
Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Marmara University, İstanbul, Turkey.
Different dosages of valaciclovir for the treatment of herpes zoster in adults: A randomized clinical study.
J Clin Pharm Ther
June 2021
Department of Dermatology, the Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.
What Is Known And Objective: The dosages of valaciclovir used for herpes zoster treatment recommended by Chinese pharmaceutical companies can differ considerably from those reported in the literature. This randomized clinical study compares the efficacy and safety of different oral valaciclovir doses for the treatment of herpes zoster in adults.
Methods: A total of 214 patients with herpes zoster were enrolled and randomized into two groups according to age: 98 patients in the 18-44-year group (younger patients) and 116 patients in the 45-74-year group (middle-aged and elderly patients).